With Covid-19 contract work growing at a rapid clip, the biggest CDMOs are taking the opportunity — and a windfall of cash — to carve out bigger footprints. At Thermo Fisher Scientific, the time’s never been better for a farsighted global expansion that will greatly expand its manufacturing capacity and add redundancy to the supply chain.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,